Compare AU
Compare ESTX vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X Euro Stoxx 50 ETF (ESTX) and the BetaShares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
ESTX | DRUG | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 67 | 59 |
Median incremental investment | $1,008.51 | $920.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,908.20 | $2,005.21 |
Average age group | > 35 | 26 - 35 |
Key Summary
ESTX | DRUG | |
---|---|---|
Strategy | ESTX.AX was created on 2016-07-19 by ETFS. The fund's investment portfolio concentrates primarily on large cap equity. ETFS EURO STOXX 50 ETF (ESTX.AX) aims to provide investors with a return that (before fees and expenses) tracks the performance of the EURO STOXX 50 Index by holding all of the shares that make up the index closely in proportion to their index weights. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | ASML Holding NV (8.06 %) SAP SE (7.33 %) Lvmh Moet Hennessy Louis Vuitton SE (4.61 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Information Technology (34.50 %) Industrials (24.16 %) Consumer Discretionary (11.01 %) | Other (75.65 %) Communication Services (33.53 %) Health Care (24.23 %) |
Top 3 countries | France (36.93 %) Germany (27.26 %) Netherlands (16.92 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.35 % | 0.57 % |
Key Summary
ESTX | DRUG | |
---|---|---|
Issuer | ETFS | BetaShares |
Tracking index | Euro STOXX 50 | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.35 % | 0.57 % |
Price | $96.40 | $8.35 |
Size | $174.606 million | $183.750 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 3.24 % | 1.89 % |
Market | ASX | ASX |
First listed date | 21/07/2016 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ESTX | DRUG | |
---|---|---|
Popularity | Low | Low |
Pearlers invested | 67 | 59 |
Median incremental investment | $1,008.51 | $920.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,908.20 | $2,005.21 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
ESTX | DRUG | |
---|---|---|
Pros |
|
|
Cons |
|
|
ESTX | DRUG |
---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |